Which molecular biomarkers do you favor to risk stratify patients (without CV risk factors) before and after undergoing treatment with cardiotoxic cancer treatments?

In general, troponin, NTproBNP or BNP, and lipid panel are the main biomarkers I use for CV risk stratification prior to cancer therapy. Baseline troponin and NTproBNP are primarily useful for cancer therapies that may cause cardiomyopathy or myocarditis (i.e. anthracyclines, anti-HER2 therapies, VEGF signaling pathway inhibitors, proteasome inhibitors, immune checkpoint inhibitors, CAR-T). Patients with baseline biomarker abnormalities should be started on cardioprotective therapies (i.e. beta-...